NASDAQ:CBPO - China Biologic Products Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $101.09 -0.17 (-0.17 %) (As of 07/19/2018 05:20 AM ET)Previous Close$101.26Today's Range$100.00 - $101.8452-Week Range$71.85 - $107.44Volume183,900 shsAverage Volume412,234 shsMarket Capitalization$3.36 billionP/E Ratio22.16Dividend YieldN/ABeta1.41 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin for intravenous injection products for original and secondary immunoglobulin deficiency, and auto-immune deficiency diseases; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing immune globulin intravenous; human antithrombin III; Caprylate/Chromatography Purified and 20 nm virus filtration; human coagulation factor IX; human cytomegalovirus immunoglobulin; and human fibrin sealant products. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China. Receive CBPO News and Ratings via Email Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:CBPO CUSIPN/A Webwww.chinabiologic.com Phone86-10-6598-3111 Debt Debt-to-Equity RatioN/A Current Ratio6.51 Quick Ratio4.55 Price-To-Earnings Trailing P/E Ratio22.16 Forward P/E Ratio21.46 P/E Growth1.65 Sales & Book Value Annual Sales$370.41 million Price / Sales9.04 Cash Flow$4.6435 per share Price / Cash21.77 Book Value$20.05 per share Price / Book5.04 Profitability EPS (Most Recent Fiscal Year)$4.95 Net Income$67.94 million Net Margins17.76% Return on Equity17.29% Return on Assets14.89% Miscellaneous Employees1,799 Outstanding Shares33,130,000Market Cap$3,355.03 China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions What is China Biologic Products' stock symbol? China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO." How were China Biologic Products' earnings last quarter? China Biologic Products Holdings Inc (NASDAQ:CBPO) announced its earnings results on Friday, May, 4th. The biopharmaceutical company reported $1.21 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.22 by $0.01. The biopharmaceutical company earned $112.50 million during the quarter, compared to analyst estimates of $118.25 million. China Biologic Products had a net margin of 17.76% and a return on equity of 17.29%. China Biologic Products's revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the business earned $1.32 earnings per share. View China Biologic Products' Earnings History. When is China Biologic Products' next earnings date? China Biologic Products is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for China Biologic Products. What price target have analysts set for CBPO? 2 analysts have issued 12 month target prices for China Biologic Products' shares. Their predictions range from $97.00 to $105.00. On average, they expect China Biologic Products' stock price to reach $101.00 in the next twelve months. This suggests that the stock has a possible downside of 0.1%. View Analyst Ratings for China Biologic Products. What is the consensus analysts' recommendation for China Biologic Products? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting China Biologic Products? China Biologic Products saw a decrease in short interest in June. As of June 29th, there was short interest totalling 1,235,909 shares, a decrease of 31.4% from the June 15th total of 1,801,541 shares. Based on an average daily trading volume, of 589,014 shares, the days-to-cover ratio is currently 2.1 days. Currently, 5.4% of the shares of the company are short sold. View China Biologic Products' Current Options Chain. Who are some of China Biologic Products' key competitors? Some companies that are related to China Biologic Products include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Regenxbio (RGNX) and Momenta Pharmaceuticals (MNTA). Who are China Biologic Products' key executives? China Biologic Products' management team includes the folowing people: Mr. Xiaoying Gao, Chairman, Pres & CEO (Age 67)Mr. Ming Yang, Chief Financial Officer (Age 46)Mr. Ming Yin, Sr. Corp. VP (Age 40)Ms. Zhijing Liu, Corp. VP (Age 64)Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 53) Has China Biologic Products been receiving favorable news coverage? Media stories about CBPO stock have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. China Biologic Products earned a news impact score of 0.13 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.34 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are China Biologic Products' major shareholders? China Biologic Products' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.07%). Company insiders that own China Biologic Products stock include David Gao, Ming Yang, Sean Shao, Wenfang Liu and Zhijing Cbpo Liu. View Institutional Ownership Trends for China Biologic Products. Which institutional investors are buying China Biologic Products stock? CBPO stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co.. View Insider Buying and Selling for China Biologic Products. How do I buy shares of China Biologic Products? Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is China Biologic Products' stock price today? One share of CBPO stock can currently be purchased for approximately $101.09. How big of a company is China Biologic Products? China Biologic Products has a market capitalization of $3.36 billion and generates $370.41 million in revenue each year. The biopharmaceutical company earns $67.94 million in net income (profit) each year or $4.95 on an earnings per share basis. China Biologic Products employs 1,799 workers across the globe. How can I contact China Biologic Products? China Biologic Products' mailing address is JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD 18TH FLOOR, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected] MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 251 (Vote Outperform)Underperform Votes: 269 (Vote Underperform)Total Votes: 520MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?